🇺🇸 FDA
Patent

US 12421273

Ectonucleotidase inhibitors and methods of use thereof

granted A61PA61P33/00

Quick answer

US patent 12421273 (Ectonucleotidase inhibitors and methods of use thereof) held by ANTENGENE THERAPEUTICS LIMITED expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ANTENGENE THERAPEUTICS LIMITED
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P33/00